go-v.orgdoi

Alzheimer’s disease vaccines: promises and pitfalls

Takeshi Tabira · Clinical Investigation · 2011

  • DOI 10.4155/cli.11.71
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2011

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2011

Abstract

Feasibility of immunotherapy for Alzheimer’s disease has been postulated, and numerous strategies of active and passive immunization have been applied in animals and humans. This article summarizes accumulated knowledge in clinical trials and animal experiments, and foresees the future perspective. Clinical trials have clearly shown that clearance of senile plaque amyloid is insufficient for improving clinical symptoms and signs, suggesting a possibility that in addition to plaque amyloid, amyloid b oligomers and intracellular amyloid b should be targeted. Furthermore, avoidance of autoimmune encephalitis and adverse inflammation must be considered.

Since the exact targeting molecule is unknown at present, polyclonal immunization strategies with activation of T helper type 2 T cells seem to be promising. Also prevention rather than treatment will be successful until we establish measures to cope with the progression mechanism of Alzheimer’s disease.

Open the resolved locator · 10.4155/cli.11.71

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 23:22 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.11.71
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.